Dent Neurologic

DENTNeuro_White

Uncategorized

CogMS

CogMS – A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis The present study will investigate the correlation between objective and subjective cognition in multiple sclerosis. The study will also investigate the impact of covariates such as fatigue and depression, the relationship with the Expanded Disability Status Scale (EDSS) and brain volumetrics as […]

CogMS Read More »

Generation HD-2

Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study:   25 Years to 50 Years   (Adult) Sexes Eligible for Study:   All Generation HD-2 Link

Generation HD-2 Read More »

NRX- 101

Testing the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in improving symptoms of depression as measured by the total Montgomery Åsberg Depression Rating Scale (MADRS-10) score in patients with bipolar depression and subacute suicidal ideation and behavior (SSIB) which does not require hospitalization.

NRX- 101 Read More »

Medical Request

Medical Forms Request ShareCare Request Your Medical Records PICK UP IN PERSON OF MEDICAL RECORDS IS NOT AN OPTION AT DENTIF THIS OPTION IS SELECTED ANY APPLICABLE RECORDS WILL BE MAILED. ***IF YOU ARE THE PATIENT AND ARE REQUESTING YOUR OWN RECORDS, PLEASE HAVE YOUR GOVERNMENT ISSUED PHOTO ID READY (license, passport, military ID) AS

Medical Request Read More »

X-TOLE: XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-Label Extension

A clinical research study is underway for people with focal epilepsy currently taking 1-3 anti-epileptic drugs that are still experiencing frequent seizures. Three doses of investigational drug are being studied and some participants will be assigned placebo. All participants will receive active study on the extension study.

X-TOLE: XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-Label Extension Read More »

Scroll to Top